Articles tagged with Lung Cancer
An experimental immunotherapy using a protein called MAGE-A3 is being tested to prevent lung cancer recurrence in patients who have undergone surgical removal of their tumor. The therapy has shown promising results in clinical trials, offering a potential new weapon against non-small cell lung cancer.
Researchers at MIT discovered that restoring the p53 gene function can slow down the spread of malignant lung tumors in mice, but not in benign ones. The study suggests that p53 restoration could help prevent aggressive cancers from metastasizing.
A new study finds that a less invasive method for determining lung cancer stage improves detection of metastases and reduces surgical procedures. The method, which combines endosonography and ultrasound, was more effective than traditional surgical staging in identifying patients who needed further treatment.
A new inhalable dry powder treatment for lung cancer has been shown to significantly increase survival rates, with over 80% of mice surviving for more than 90 days. The treatment method is also less invasive than traditional options, reducing the risk of side effects and improving overall patient outcomes.
A gene-based test accurately identified a subgroup of very high-risk smokers who accounted for over 50% of all lung cancer cases. The study found that targeting these individuals with low-dose CT screening could significantly improve the number of early-stage lung cancer cases found, making screening more cost-effective.
A study of adolescents found that less than 2% met annual preventive care visit recommendations, highlighting the need for better access to care. Meanwhile, a survey of family physicians revealed that many refer patients elsewhere for vaccines due to inadequate payment and lack of participation in federally-funded programs.
Researchers found distinct DNA alterations in lung tumors from smokers and never-smokers, suggesting two possible disease pathways. The study suggests that lung cancers in never-smokers require further investigation to improve detection and treatment strategies.
A gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to a clinical study. The test, Respiragene, resulted in 32% of smokers quitting altogether and another 48% reducing their cigarette intake.
Researchers at Hebrew University of Jerusalem discovered that Vav1 plays a wider role in several types of cancer than previously thought. The discovery has implications for targeting this gene in cancer research and identifying potential therapeutic targets.
A national study conducted by the National Cancer Institute found that CT scanning can reduce lung cancer deaths by 20% in former and current heavy smokers. The study, which involved over 53,000 participants, compared low-dose helical CT with standard chest X-ray screening.
Researchers found that screening for lung cancer using helical CT scanning reduced lung cancer deaths by 20 percent compared to chest X-rays. The study also showed overall deaths due to any factor were 7 percent lower in those screened with low-dose helical CT.
A new study published in the New England Journal of Medicine found that crizotinib caused tumors to stop growing, shrink or disappear in 57-33 percent of patients with a specific genetic mutation. This represents a significant improvement over the current standard treatment, which has a response rate of around 15 percent.
Researchers found lung adenocarcinomas in young patients with pediatric cancers, displaying similar gene mutations as adult cases. The tumors may occur prior to chemotherapy treatment and are not always secondary malignancies.
A study published in the New England Journal of Medicine found that over half of patients with a specific type of lung cancer responded well to a new targeted treatment called crizotinib. The medication targets the gene driving the cancer and has been shown to improve patient outcomes, including reduced tumor growth and improved qualit...
Researchers found that maternal KIRs interacting with fetal HLA-C molecules determine trophoblast invasion, affecting recurrent miscarriage and preeclampsia. Meanwhile, a new approach to treating thrombocytopenia involves infusing mature megakaryocytes into mice to generate functional platelets.
Researchers at IRIC discovered a protein complex, EJC, that controls the production of MAPK protein, which acts directly on cells. Targeting this complex could prevent abnormal signal transmission that triggers several cancers.
A biomarker called TCF21 has shown promise in developing a potential screening test for early-stage lung cancer. The biomarker's abnormal expression was found in over 80% of non-small-cell lung cancers, suggesting its potential as a diagnostic tool.
A Phase IIb/III trial shows afatinib benefits patients with lung adenocarcinoma whose cancer progressed after chemotherapy and erlotinib or gefitinib. Patients receiving afatinib experienced delayed disease progression and greater tumor shrinkage, but no significant difference in overall survival.
A Phase II study of the new-generation lung cancer drug PF-299 has shown impressive results in preventing disease progression when administered as a first-line treatment in patients with advanced disease. The study found that 85% of patients with EGFR mutations remained progression-free for at least nine months.
In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.
Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.
A new drug targeting the MET receptor added benefit to erlotinib in patients with advanced lung cancer who express MET, improving overall survival and progression-free survival
A new clinical study reveals a technique called partial wave spectroscopic microscopy can differentiate individuals with lung cancer from those without, even in lifetime smokers or COPD patients. The findings suggest that this minimally invasive test could lead to personalized screening for lung cancer, the leading cause of cancer deat...
Researchers developed a method to detect early signs of lung cancer by examining cheek cells using biophotonics technology. The test, called partial wave spectroscopic (PWS) microscopy, shows promise in prescreening patients at high risk for the disease.
A retrospective study found that African-American patients had a lower median overall survival rate due to factors such as age, stage, and type of treatment, rather than their race. Patients of other races, including Asian and Hispanic patients, had a better disease prognosis.
A new study published in the Journal of Thoracic Oncology found that approximately half of advanced non-small cell lung cancer patients received chemotherapy treatment, exceeding previous estimates. The retrospective analysis showed age and insurance type were associated with chemotherapy administration.
The TRUST study found that erlotinib significantly increased survival for patients with previously treated advanced NSCLC. Certain patient groups, such as adenocarcinoma, women, and Asian ethnicity, showed greater tumor responses to EGFR TK inhibitors.
A study by the University of Melbourne found that close relatives of women diagnosed with breast cancer before age 35 have a higher risk of developing other cancers. These include prostate, lung, brain, and urinary tract cancers, with increased risks ranging from 2 to 8 times higher than expected.
Researchers at Boston University School of Medicine have discovered a key protein factor, Ets1, involved in the progression of lung cancer. The study aims to identify new therapeutic targets to block tumor growth and metastasis, offering hope for improved patient outcomes.
A 40-year-long tobacco control program in California has led to significant reductions in smoking rates, resulting in lower lung cancer mortality. The study credits the state's aggressive tax on cigarettes and comprehensive tobacco control efforts.
Researchers found that African-American patients with non-small cell lung cancer have similar rates of EGFR mutations, making targeted therapies like erlotinib a viable option. This discovery challenges previous assumptions about racial disparities in lung cancer treatment.
The study found that radiation exposure increases the risk of both first and second cancers to a similar degree, with higher risks for radiation-sensitive cancers like lung, colon, breast, thyroid, and bladder cancers. Cancer survivors with a history of radiation exposure should continue to be closely monitored for second cancers.
Researchers at UT Southwestern Medical Center have found that overexpressing microRNA-21 promotes the formation, growth and survival of new tumors in mice with non-small-cell lung cancer. The study suggests that inhibiting miR-21 could be a therapeutic approach to treating the disease.
A study by Heike Allgayer's team found that micro-RNA miR-200c inhibits the motility and invasive capacity of non-small cell lung cancer cells. Higher miR-200c levels were associated with increased tissue-anchoring molecules and lower metastasis rates.
A genetic signature has been identified that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and may benefit from chemotherapy after surgery. The study found that the 15-gene signature predicted aggressive disease in 62 patients, and those with agg...
A study found that tumor budding is a distinct morphologic feature with biologic and prognostic significance in lung adenocarcinoma, significantly linked to aggressive disease characteristics. The presence of tumor budding was also associated with lower five-year survival rates.
A study published in Journal of Thoracic Oncology found that using the histoculture drug response assay to guide chemotherapy improves lung cancer survival and prognosis for patients who have undergone surgery. The use of adjuvant chemotherapy based on assay results showed a higher five-year survival rate compared to traditional treatm...
A researcher at Michigan State University is studying the role of the innate immune system in protecting against lung cancer. Alison Bauer's work may lead to new approaches to prevent, identify and treat lung cancer.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have found that adult stem cells vital for lung repair are associated with a poor prognosis in patients who develop cancer. These cells may mutate into cancer-causing stem cells, making them a potential target for prevention strategies and new targeted therapies.
A recent study published in JNCI Journal of the National Cancer Institute found that estrogen alone was not associated with increased lung cancer mortality among postmenopausal women. In contrast, combined hormone therapy showed a statistically significant increase in breast cancer incidence and a reduction in colorectal cancer.
Research published in the Journal of Thoracic Oncology defines timeframes for declaring early stage lung cancer cured. Patients with stage IA NSCLC without vascular invasion can be considered cured after five years, while those with vascular invasion require longer follow-up until at least nine years.
A study of 342 early-stage lung cancer survivors found that nearly 60% experienced long-term dyspnea, with associated risk factors including reduced physical activity and depression. Targeting post-treatment rehabilitation strategies to improve breathlessness may be effective in improving outcomes.
A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients, increasing with disease severity. The study suggests that these circulating cells could be used to diagnose lung cancer earlier and monitor response to therapy.
A study from American Cancer Society researchers found that more time spent sitting is associated with a higher risk of mortality, particularly in women. The association remained virtually unchanged after adjusting for physical activity level, suggesting that reducing sedentary behavior can help lower death rates.
Researchers confirm bevacizumab's safety in treating advanced non-squamous non-small cell lung cancer when combined with chemotherapy. The comprehensive study found no new safety signals beyond previously known toxicities, including life-threatening effects like bleeding.
A new method of tissue banking enables researchers to obtain high-quality RNA samples from lung tumor biopsies, increasing the number and type of tumors available for gene expression studies. This improves personalized medicine prospects for lung cancer patients.
A study analyzed the probability of surviving nine types of cancer in Spain, comparing rates to European averages. The results show varying survival rates for different cancers, with some types having high recovery rates (e.g., testicular and skin melanoma) while others have lower rates (e.g., lung cancer).
Research features standardized approaches to measure and compare tumor size in lung cancer. The use of precise quantitation tools may allow for more rapid evaluation of the success or failure of drug candidates in clinical trials.
Cancer stem cells have been identified in a model of human lung cancer, but their uniqueness varies between tumors depending on the tumor's genetic signature. The study suggests that targeting specific cancer cell populations based on the tumor genotype may lead to personalized and effective treatments.
Researchers discovered that asbestos exposure leads to the release of high-mobility group box 1 protein (HMGB1), which promotes tumor growth and inflammation. Elevated levels of HMGB1 in patients exposed to asbestos may enable simple serological testing to identify at-risk individuals.
A new UNC study found that African Americans with two or more medical conditions had almost zero surgeries, while white patients in the same situation had surgery just as often. The study also found that lack of a regular source of care led to significantly lower surgical rates for black patients.
Researchers found that administering nab-paclitaxel weekly resulted in a 48% response rate and less severe side effects compared to every-three-week dosing. The study showed improved anti-tumor activity and reduced nerve damage with the novel formulation.
A study analyzing nearly 400,000 participants found that increased blood levels of vitamin B6 and methionine were associated with a reduced risk of developing lung cancer. The findings suggest these nutrients may play a role in inhibiting cancer development, offering potential for dietary modification to reduce cancer risk.
Researchers analyzed surgical outcomes of non-small cell lung cancer patients over 30 years, finding improved survival rates with earlier stage diagnoses. The increase in patients diagnosed with early-stage adenocarcinoma is thought to contribute significantly to the favorable results.
A recent study found that patients with early-stage lung cancer often forego surgery due to misconceptions about prognosis, communication with doctors, and personal life after treatment. The research also highlights racial disparities in surgical rates among black patients compared to their white counterparts.
A recent study uses genomic analysis to understand complex cellular signals driving lung cancer's deadly spread. The research identifies specific molecules linked to non-small cell lung cancer's (NSCLC) invasive and metastatic processes, providing a basis for effective therapies.
A meta-analysis of publicly available data from randomised trials found that patients taking ARBs had a significantly increased likelihood of new cancer diagnosis compared with patients in control groups. The study also found a modestly increased risk of lung cancer among ARB users, but no significant excess in cancer deaths.
A decade-long Phase III clinical trial found that selenium has no benefit in reducing the risk of developing lung cancer, either a recurrence or second primary malignancy. The study involved 1,522 Stage I non-small cell lung cancer patients and showed that selenium had minimal side effects but failed to demonstrate any protective effect.
Vandetanib significantly prolongs progression-free survival and improves response rates compared to standard chemotherapy alone in previously treated advanced NSCLC patients. The addition of vandetanib also reduces symptoms and increases time to worsening of symptoms.
A study published in Cancer journal found that cofilin (CFL1) levels can predict patient prognosis and identify potential non-responders to treatment. High levels of CFL1 correlate with aggressive tumor behavior and resistance to certain anticancer drugs.